The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid a re-evaluation of growth prospects within the healthcare sector, Morgan Stanley has downgraded ResMed (RMD) from Overweight to Equalweight. The bank significantly adjusted its price target for the stock downward to $230 from a previous $286. This move reflects a shift in the investment bank's valuation and a more cautious outlook on the company's performance relative to the broader market.
The downgrade comes as medical device manufacturers navigate increasing competitive pressures, with peers like Philips reporting stabilized supply chains but cautious annual guidance in recent earnings calls. Per market data, the narrowing gap between the new price target and current trading levels underscores analyst concerns regarding margin sustainability in an inflationary environment, as the U.S. CPI rose 4.2% year-over-year according to data from June 10, 2026.
Sign in to access this content
Sign InResMed shares closed at $192.74 (close June 15, 2026), having traded between a high of $197.41 and a low of $191.65 during that session. Investors are now watching for support levels near the recent lows as they await further catalysts. Key upcoming events include the U.S. Initial Jobless Claims on June 11, 2026, which may influence broader market sentiment and risk appetite for healthcare growth stocks.